Company news

Mesoblast Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Half Yearly Report and Accounts (including Appendix 4D)

February 16, 2016

MSB Therapy Shows Benefit In First Cohort Of RA Patients

February 15, 2016

Phase 3 Heart Failure Trial Size Substantially Reduced

February 11, 2016

US Govt Grants for Further Development of Stem Cell Products

February 10, 2016

USA FDA Clears Phase 2 Trial For Cervical Spinal Fusion

February 10, 2016

Type 2 Diabetes Trial Results Published In Diabetes Care

February 10, 2016

Strategic Update and Q1 Financial Results Presentation

February 10, 2016

Rheumatoid Arthritis New Major Clinical Target for MSB

February 10, 2016

Reversed Arterial Dysfunction And Inflammation in RA Model

February 10, 2016

Results Show Improved Survival in Children with GVHD

February 10, 2016

Response to ASX Price Query Letter

February 10, 2016

Quarterly Results Filed on Form 6-K with SEC

February 10, 2016

Positive Results Using Adult Stem Cells for Type 2 Diabetes

February 10, 2016

Positive Outcome From FDA Meeting For Diabetes Program

February 10, 2016

Positive interim results in phase 2 trial for disc repair

February 10, 2016

Positive EMA Meeting For Phase 3 Disc Repair Program

February 10, 2016

Positive Diabetic Nephropathy Trial Results

February 10, 2016

P3 trial initiated, positive 24 mth P2 results in back pain

February 10, 2016

MSB Unveils Path to Bring its Key Products to Market

February 10, 2016

MSB to Begin Phase 2 Trial of MPCs in Diabetic Nephropathy

February 10, 2016

MSBs Japan Licensee Receives Pricing For TEMCELL

February 10, 2016

MSB Partner JCR Receives Recommendation For Japan Approval

February 10, 2016

MSB Cell Therapy Shows Greatest Effect In Advanced CHF

February 10, 2016

Mesoblast Update on Valeant Proposal to Cephalon

February 10, 2016

Mesoblast To Acquire Angioblast Systems, 37M Capital Raising

February 10, 2016

Mesoblast Receives $5.8m From Aus Govt For R&D

February 10, 2016

Mesoblast Provides Strategic Update and Q1 Financial Results

February 10, 2016

Mesoblast Lists On Nasdaq

February 10, 2016

Mesoblast Enters into Agreements to Raise A$170million

February 10, 2016

Key US patent granted for treatment of degenerated discs

February 10, 2016

Key US Patent Granted For Heart, Stroke, Vascular Diseases

February 10, 2016

Key USA Patents Increase Commercial Rights and Indications

February 10, 2016

Key Patent Allowed In Japan For Heart Diseases, Stroke

February 10, 2016

Key Mesoblast Patent Claims Upheld in Europe

February 10, 2016

Key Mesenchymal Precursor Cell Patent Granted in Japan

February 10, 2016

Key Manufacturing Agreement with FDA for Phase 3 Trials

February 10, 2016

Improved Survival in Children with GvHD After Cell Therapy

February 10, 2016

Full Japanese Approval For MSC Product

February 10, 2016

FDA Clears Phase 3 Heart Failure Trial

February 10, 2016

FDA clears phase 2 clinical trial for rheumatoid arthritis

February 10, 2016

Fast Track Access To Potential Japan Investment Incentives

February 10, 2016

Diabetic Nephropathy Results To Be Presented At ADA Meeting

February 10, 2016

Circulation Research Publishes AMI Preclinical Trial Results

February 10, 2016

Chronic Low Back Pain Results Presented at NASS

February 10, 2016

CHF Phase 2 Trial Results Published In Circulation Research

February 10, 2016

Celgene And Mesoblast Extend Agreement

February 10, 2016

Celgene And Mesoblast Enter Into Agreement

February 10, 2016

Angioblast Stockholders Approve Acquisition By Mesoblast

February 10, 2016

← Newer news releases

Calls

The 5 newest of 10 calls. Every call is listed under its year.

Decks

The 5 newest of 105 decks. Every deck is listed under its year.